Published: June 6, 2025 | John Beeler, Ph.D.
“Over the past few years, the biotech industry has endured a long winter. Investor enthusiasm has cooled, valuations have dropped and companies have had to tighten their focus. Yet one area continues to attract attention and investment – the promise of artificial intelligence (AI) to revolutionize drug discovery.Several AI-first biotech companies, or “techbios” as they are sometimes called, have secured massive funding during this difficult period. These include Isomorphic Labs’s latest US$600 million round in March 2025 and AI startup Xaira Therapeutics’ US$1 billion backing late last year.
Many AI-first biotech companies are built on the belief that machine learning and algorithms using existing data can accelerate the process of finding and designing new drugs. It’s true that AI can identify new potential drug candidates, but the challenges these companies have faced in getting drugs through clinical testing have made one thing very clear: AI alone is not enough to solve drug discovery’s most persistent challenges.
If we want true, sustainable innovation in drug development – and a financially viable healthcare system – we must reinvest in biology with the same urgency and passion currently fueling AI…”
Read the full article at Technology Networks Drug Discovery here: Investing in Biology: The Key to Sustainable Innovation in Drug Development and Healthcare
